Shire to sell its oncology business to Servier for $2.4 billion17 Apr 2018
Sale of oncology business unlocks embedded value within Shire’s portfolio and sharpens focus on core areas reinforcing the company's leadership in rare diseases.
Shire has entered into a definitive agreement with Servier to sell its oncology business for $2.4 billion. Shire’s oncology business includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-US rights to Onivyde (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early-stage immuno-oncology pipeline collaborations.
Flemming Ornskov, Shire CEO, commented: “This transaction is a key milestone for Shire, demonstrating the clear value embedded in our portfolio. While the Oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy. We will continue to evaluate our portfolio for opportunities to unlock further value and sharpen our focus on rare disease leadership with selective disposals of non-strategic assets.
“We are confident that Servier will continue to invest in this business and our colleagues who are expected to transfer as part of the transaction in order to meet the needs of cancer patients globally.
“The proceeds from the transaction increase optionality and Shire’s Board will consider returning the proceeds of the sale to shareholders through a shareholder-approved share buyback after the current offer period regarding Takeda’s possible offer for Shire concludes.”
Olivier Laureau, Servier Group President, commented: “The acquisition of Shire's oncology franchise enables Servier to meet its strategic ambitions to become a global key player in oncology. As an essential step in the evolution of the Group, this acquisition allows us to establish a direct commercial presence in the United States, the world's leading pharmaceuticals market, and to strengthen our portfolio of marketed products in the territories where Servier is already present. Our goal is to bring these treatments to greater numbers of cancer patients around the world. We thoroughly look forward to welcoming Shire’s oncology teams who will join Servier after the closing."
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
India to have strongest global growth in 2019?
4 Dec 2018
Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.Read more
Catalent to expand biologics packaging capabilities
3 Dec 2018
Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.Read more
Merck successfully divests Consumer Health
2 Dec 2018
Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.Read more
Digital manufacturing is a top priority for life sciences
29 Nov 2018
Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Hikma announces injectable licensing agreement
27 Nov 2018
Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation